For example, halofuginone, an anticoccidial drug, is a TGF-β signaling inhibitor that had antitumor effects and reduced collagen synthesis in animal models of several solid cancers (lung, melanoma, breast, pancreas, etc.)[66], and had synergetic effect with chemotherapeutic drugs overcoming chemotherapeutic resistance in lung, prostate, and colorectal cancers, and it is currently explored in several clinical trials in bladder cancer, AIDS-related Kaposi sarcoma, and in advanced solid tumors [67]. This evidence concerns the gene TGFB1 and urinary bladder carcinoma.